Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

0.8790 +0.0420 (+5.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Research Links Key Proteins to the Growth of Brain Tumors
Via Investor Brand Network
New Scanning Method Could Improve How Brain Tumors are Treated
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar
Via Investor Brand Network
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287
Via ACCESS Newswire
New Study Shows TTFields Amplify Immune Attack Against Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Via ACCESS Newswire
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit
Via Investor Brand Network
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
Via ACCESS Newswire
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
Via Investor Brand Network
Topics Lawsuit
Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis
Via Investor Brand Network
Experts Say New Test for Brain Tumors is a Game-Changer
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Simple Hand Motion Test Could Reveal Undetected Brain Tumor
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor
Via Investor Brand Network
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications
Via Investor Brand Network
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
Via ACCESS Newswire
Study Reveals Early Development of Pediatric Brain Tumors in Specialized Nerve Cells
Via Investor Brand Network
AI Can Predict the Recurrence of Brain Tumors in Kids, Study Finds
Via Investor Brand Network
Topics Artificial Intelligence
Study Identifies Key Enzyme That Could Be Targeted to Fight Brain Cancers
Via Investor Brand Network
The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035
Via Investor Brand Network
Study Uncovers Drivers of Brain Tumor Growth, Could Open New Treatment Approaches
Via Investor Brand Network
Pitt Researchers Develop Diagnostic Tool for Profiling Pediatric Brain Cancers
Via Investor Brand Network
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position
Via Investor Brand Network
Firefighters Have an Increased Chance of Having Gene Mutations Associated with Brain Cancer, Study Says
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial
Via Investor Brand Network
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Via ACCESS Newswire
Study Finds Experimental Drug Prolongs the Survival of Glioblastoma Patients
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.